Emmanuel Stip1, Jean Lachaine2. 1. Département de Psychiatrie, Université de Montréal Faculté de Médecine, C.P. 6128, Succursale Centre-Ville, Montréal, Québec H3C 3J7, Canada. 2. CR-CHUM, University of Montréal, Montréal, Québec, Canada Faculty of Pharmacy, University of Montréal, Montréal, Québec, Canada.
Abstract
BACKGROUND: Long-acting injectable antipsychotics (LAI-AP) for patients with schizophrenia (SCZ) have saved significant healthcare costs. However, the cost effectiveness of LAI-AP for patients with other mental disorders has yet to be established. The goal of this study was to evaluate the impact of early initiation of LAI-AP medications on healthcare resource utilization (HRU). Drawing on the Quebecois universal healthcare program (RAMQ), we conducted a nationwide prospective cohort study of LAI-AP under real-world conditions. METHODS: This study was performed using a representative sample of patients newly treated with LAI-AP (n = 3957) who were covered by the Québec Health Insurance Plan. The index date was defined as the date of the first prescription for LAI-AP between 1 January 2008 and 31 March 2012. We collected (a) the demographics and patient characteristics; (b) the treatment characteristics index drug, speciality of the principal prescriber, prescriptions of LAI-AP; and (c) HRU and costs. Two comparisons were made between (a) non-SCZ users of LAI-AP and SCZ users of LAI-AP; and (b) patients with SCZ using first-generation antipsychotic LAI-AP (FGA-LAI) and second-generation antipsychotic LAI-AP (SGA-LAI). RESULTS: In the people with SCZ group, 976 patients were on an SGA-LAI, and 1020 patients were on an FGA-LAI; 41.9% of all users were on risperidone LAI-AP during this period and 17.9% were on zuclopenthixol decanoate. The number of hospitalizations was reduced by half. Durations were also significantly reduced. The total healthcare cost savings for all users were C$29,876 per patient/per year. Younger patients tended to receive more SGA-LAI than FGA-LAI: 29% versus 13%. The percentage of general practitioners who prescribe LAI-AP is higher in the FGA-LAI group than in the SGA-LAI group: 19% versus 13%. For psychiatrist prescribers, it is the opposite: 86% (SGA-LAI) versus 79% (FGA-LAI). The concomitant use of oral antipsychotics (OAP) in the year following index date is higher in the FGA-LAI group: 75% versus 43%. The number of hospitalization days was reduced by 31.5 days in the FGA-LAI group and 38.8 days in the SGA-LAI group. Cost savings were of C$31,924 in the FGA-LAI group and of C$39,100 in the SGA-LAI group. CONCLUSION: The initiation of LAI-AP saved significant costs to the province of Québec compared with the previous year. Initiation of a LAI-AP resulted in lower resource use. Higher medication costs were offset by lower inpatient and outpatient costs.
BACKGROUND: Long-acting injectable antipsychotics (LAI-AP) for patients with schizophrenia (SCZ) have saved significant healthcare costs. However, the cost effectiveness of LAI-AP for patients with other mental disorders has yet to be established. The goal of this study was to evaluate the impact of early initiation of LAI-AP medications on healthcare resource utilization (HRU). Drawing on the Quebecois universal healthcare program (RAMQ), we conducted a nationwide prospective cohort study of LAI-AP under real-world conditions. METHODS: This study was performed using a representative sample of patients newly treated with LAI-AP (n = 3957) who were covered by the Québec Health Insurance Plan. The index date was defined as the date of the first prescription for LAI-AP between 1 January 2008 and 31 March 2012. We collected (a) the demographics and patient characteristics; (b) the treatment characteristics index drug, speciality of the principal prescriber, prescriptions of LAI-AP; and (c) HRU and costs. Two comparisons were made between (a) non-SCZ users of LAI-AP and SCZ users of LAI-AP; and (b) patients with SCZ using first-generation antipsychotic LAI-AP (FGA-LAI) and second-generation antipsychotic LAI-AP (SGA-LAI). RESULTS: In the people with SCZ group, 976 patients were on an SGA-LAI, and 1020 patients were on an FGA-LAI; 41.9% of all users were on risperidone LAI-AP during this period and 17.9% were on zuclopenthixol decanoate. The number of hospitalizations was reduced by half. Durations were also significantly reduced. The total healthcare cost savings for all users were C$29,876 per patient/per year. Younger patients tended to receive more SGA-LAI than FGA-LAI: 29% versus 13%. The percentage of general practitioners who prescribe LAI-AP is higher in the FGA-LAI group than in the SGA-LAI group: 19% versus 13%. For psychiatrist prescribers, it is the opposite: 86% (SGA-LAI) versus 79% (FGA-LAI). The concomitant use of oral antipsychotics (OAP) in the year following index date is higher in the FGA-LAI group: 75% versus 43%. The number of hospitalization days was reduced by 31.5 days in the FGA-LAI group and 38.8 days in the SGA-LAI group. Cost savings were of C$31,924 in the FGA-LAI group and of C$39,100 in the SGA-LAI group. CONCLUSION: The initiation of LAI-AP saved significant costs to the province of Québec compared with the previous year. Initiation of a LAI-AP resulted in lower resource use. Higher medication costs were offset by lower inpatient and outpatient costs.
Authors: Jari Tiihonen; Jari Haukka; Mark Taylor; Peter M Haddad; Maxine X Patel; Pasi Korhonen Journal: Am J Psychiatry Date: 2011-03-01 Impact factor: 18.112
Authors: Jari Tiihonen; Ellenor Mittendorfer-Rutz; Maila Majak; Juha Mehtälä; Fabian Hoti; Erik Jedenius; Dana Enkusson; Amy Leval; Jan Sermon; Antti Tanskanen; Heidi Taipale Journal: JAMA Psychiatry Date: 2017-07-01 Impact factor: 21.596
Authors: William G Honer; Allen E Thornton; Eric Y H Chen; Raymond C K Chan; Jessica O Y Wong; Andrea Bergmann; Peter Falkai; Edith Pomarol-Clotet; Peter J McKenna; Emmanuel Stip; Richard Williams; G William MacEwan; Kishor Wasan; Ric Procyshyn Journal: N Engl J Med Date: 2006-02-02 Impact factor: 91.245
Authors: Stefan Leucht; Magdolna Tardy; Katja Komossa; Stephan Heres; Werner Kissling; Georgia Salanti; John M Davis Journal: Lancet Date: 2012-05-03 Impact factor: 79.321
Authors: Taishiro Kishimoto; Katsuhiko Hagi; Masahiro Nitta; Stefan Leucht; Mark Olfson; John M Kane; Christoph U Correll Journal: Schizophr Bull Date: 2018-04-06 Impact factor: 9.306
Authors: Juan Antonio García-Carmona; Jorge Simal-Aguado; María Pilar Campos-Navarro; Francisco Valdivia-Muñoz; Alejandro Galindo-Tovar Journal: Clin Drug Investig Date: 2020-05 Impact factor: 2.859
Authors: Kai On Wong; Scott W Klarenbach; Karen J B Martins; Pierre Chue; Serdar M Dursun; Mark Snaterse; Alexis Guigue; Helen So; Huong Luu; Khanh Vu; Lawrence Richer Journal: BMC Psychiatry Date: 2022-07-02 Impact factor: 4.144
Authors: Ofer Agid; Gary Remington; Carmen Fung; Natalie M Nightingale; Marc Duclos; Gregory J Anger Journal: Can J Psychiatry Date: 2021-11-18 Impact factor: 5.321
Authors: Donica Janzen; James M Bolton; Christine Leong; I Fan Kuo; Silvia Alessi-Severini Journal: Front Pharmacol Date: 2022-05-19 Impact factor: 5.988
Authors: Martin Lambert; Pedro Sanchez; Paul Bergmans; Srihari Gopal; Maju Mathews; Annette Wooller; Katalin Pungor Journal: Neuropsychiatr Dis Treat Date: 2020-12-23 Impact factor: 2.570